Autopsy report · NCT04890353

Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke

“The interim analysis of another associated study is not very effective”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 1 year 3 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Xuanwu Hospital, Beijing

Sponsor type

University, hospital or other

Conditions

Acute Ischemic Stroke

Interventions

Dimethyl fumarate

Participants

2

Sites

1

Countries

China

Trials that died the same way

• Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
  “Interim analysis determined the study did not meet criteria to proceed” (86% match in meaning)
• Study of Pemetrexed for Second-Line Pancreas Cancer
  “At interim analysis the study did not meet the response criteria to continue” (83% match in meaning)
• Moxonidine in Patients Undergoing Vascular Surgery
  “Study was stopped after pre-definied interim analysis because of no effects” (80% match in meaning)
• Verapamil vs Steroid to Prevent Keloid Recurrence
  “Objective of study achieved after interim analysis.” (79% match in meaning)
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)
  “Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.